EYPT (EyePoint) Valuation Rank


EYPT EyePoint Inc EYPT
34 GF Score
Price $13.66
GF Value $0.83
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

EyePoint Valuation Rank Related Terms

EYPT
34GF Score
EyePoint Inc EYPT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $13.66 is trading 1545.8% above its estimated GF Value™ of $0.83. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Valuation Rank:
  • GF Value™: $0.83 vs. price of $13.66 (1545.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.66
Price
$0.83
GF Value